Hemay181
/ Tianjin Hemay Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 23, 2025
A phase Ib clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary anti-tumor efficacy of Hemay181 in patients with advanced solid tumors.
(ASCO 2025)
- P1 | "In animal Xenograft models, a tumor-to-plasma ratio of 75 fold for Hemay181, 12x Govitecan, 0.3 for Irinotecan showing tumor concentration. Hemay181 in the dose range of 36mg/m2 to 150mg/m2 shows potential therapeutic benefits, with tumor shrinkage demonstrated in advanced breast, lung, and pancreatic cancers. The benefit-risk ratio is favorable, justifying further dose optimization and expansion."
Clinical • Metastases • P1 data • PK/PD data • Anemia • Breast Cancer • Colon Cancer • Colorectal Cancer • Endocrine Disorders • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
April 19, 2025
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=51 | Recruiting | Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026
Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Oncology • Solid Tumor
April 25, 2024
Hemay181: A novel SDC (sugar linked drug conjugate) for solid tumors targeting tumor microenvironment.
(ASCO 2024)
- "Hemay181 significantly reduced tumour volume compared to irinotecan, which only slowed the tumour growth rates. In summary, the novel broad-spectrum anti-tumour drug Hemay181 has the characteristics of high water solubility, tumour-targeting ability, low toxicity and side effects on normal tissues. It is under evaluation in ongoing clinical studies."
Biomarker • Tumor microenvironment • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • TOP1
March 06, 2024
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=51 | Recruiting | Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
March 01, 2023
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=51 | Not yet recruiting | Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd
Metastases • New P1 trial • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1